PET/CT in treatment response assessment in lung cancer. When should it be recommended?
Journal
Nuclear medicine communications
ISSN: 1473-5628
Titre abrégé: Nucl Med Commun
Pays: England
ID NLM: 8201017
Informations de publication
Date de publication:
01 Dec 2023
01 Dec 2023
Historique:
medline:
9
11
2023
pubmed:
14
9
2023
entrez:
14
9
2023
Statut:
ppublish
Résumé
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Different treatment options are now possible both for surgical candidates and for those NSCLC patients deemed not suitable for surgery. Despite the treatments available, only a limited number of less advanced stages are potentially curable, with many patients suffering local recurrence or distant metastases. FDG-PET/CT is commonly used in many centers for post-treatment evaluation, follow-up, or surveillance; Nonetheless, there is no clear consensus regarding the indications in these cases. Based upon the results of a literature review and local expertise from a large lung cancer unit, we built clinical evidence-based recommendations for the use of FDG-PET/CT in response assessment. We found that in general this is not recommended earlier than 3 months from treatment; however, as described in detail the correct timing will also depend upon the type of treatment used. We also present a structured approach to assessing treatment changes when reporting FDG-PET/CT, using visual or quantitative approaches.
Identifiants
pubmed: 37706268
doi: 10.1097/MNM.0000000000001757
pii: 00006231-990000000-00208
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1059-1066Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Thandra KC, Barsouk A, Saginala K, Aluru JS, Barsouk A. Epidemiology of lung cancer. Wspolczesna Onkologia Termedia Publishing House Ltd 2021; 25:45–52.
Daly ME, Singh N, Nofisat I, Antonoff MB, Arenberg DA, Bradley J, et al. Management of stage III non-small-cell lung cancer: ASCO guideline. J Clin Oncol 2021; 40:1356–1384.
Zarogoulidis K, Zarogoulidis P, Darwiche K, Boutsikou E, Machairiotis N, Tsakiridis K, et al. Treatment of non-small cell lung cancer (NSCLC). J Thorac Dis 2013; 5(Suppl 4):S389–S396.
Schad F, Thronicke A, Steele ML, Merkle A, Matthes B, Grah C, Matthes H. Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis. PLoS One 2018; 13:e0203058. .
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, et al. Non-small cell lung cancer, version 5.2017: clinical practice guidelines in oncology. J Nat Compr Cancer Netw Harborside Press 2017; 15:504–535.
Fischer B, Lassen U, Mortensen J, Larsen S, Loft A, Bertelsen A, et al. Preoperative staging of lung cancer with combined PET–CT. N Engl J Med 2009; 361:32–39.
Kandathil A, Sibley RC, Subramaniam RM. Lung cancer recurrence: 18F-FDG PET/CT in clinical practice. Am J Roentgenol 2019; 213:1136–1144.
Sterbis E, Liang R, Trivedi P, Kwak J, Cohen Major E, Karam SD, et al. Lack of adherence to guideline-based imaging prior to subsequent radiation in patients with non-small cell lung cancer: impact on patient outcomes. J Nucl Med 2023; 64:75–81
Sheikhbahaei S, Mena E, Yanamadala A, Reddy S, Solnes LB, Wachsmann J, et al. The value of FDG PET/CT in treatment response assessment, follow-up, and surveillance of lung cancer. Am J Roentgenol American Roentgen Ray Society 2017; 208:420–433.
Scarsbrook AF, Barrington SF. PET-CT in the UK: current status and future directions. Clin Radiol W.B. Saunders Ltd 2016; 71:673–690.
He YQ, Gong HL, Deng YF, Li WM. Diagnostic efficacy of PET and PET/CT for recurrent lung cancer: a meta-analysis. Acta Radiol 2014; 55:309–317.
Kaseda K. Recent and current advances in FDG-PET imaging within the field of clinical oncology in NSCLC: a review of the literature. Diagnostics (Basel). 2020; 10:561.
Wasif Saif M, Tzannou I, Makrilia N, Syrigos K. Role and cost effectiveness of PET/CT in management of patients with cancer. Yale J Biol Med 2010; 83:53–65.
Farsad M. FDG PET/CT in the staging of lung cancer. Curr Radiopharm 2019; 13:195–203.
Choi SH, Kim YT, Kim SK, Kang KW, Goo JM, Kang CH, et al. Positron emission tomography-computed tomography for postoperative surveillance in non-small cell lung cancer. Ann Thorac Surg 2011; 92:1826–32; discussion 1832.
Huang K, Dahele M, Senan S, Guckenberger M, Rodrigues GB, Ward A, et al. Radiographic changes after lung stereotactic ablative radiotherapy (SABR) - Can we distinguish recurrence from fibrosis? A systematic review of the literature. Radiother Oncol 2012; 102:335–342.
Hellwig D, Gröschel A, Graeter TP, Hellwig AP, Nestle U, Schäfers HJ, et al. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2006; 33:13–21.
Hicks RJ, Kalff V, Macmanus MP, Ware RE, Mckenzie AF, Matthews JP, et al. The utility of 18 F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. J Nucl Med 2001; 42:1605-1613.
Ebright MI, Russo GA, Gupta A, Subramaniam RM, Fernando HC, Kachnic LA. Positron emission tomography combined with diagnostic chest computed tomography enhances detection of regional recurrence after stereotactic body radiation therapy for early stage non-small cell lung cancer. J Thorac Cardiovasc Surg 2013; 145:709–715.
de Cabanyes Candela S, Detterbeck FC. A systematic review of restaging after induction therapy for stage IIIa lung cancer: Prediction of pathologic stage. J Thorac Oncol Lippincott Williams and Wilkins 2010; 5:389–398.
Monaco L, de Bernardi E, Bono F, Cortinovis D, Crivellaro C, Elisei F, et al. The ‘digital biopsy’ in non-small cell lung cancer (NSCLC): a pilot study to predict the PD-L1 status from radiomics features of [18F]FDG PET/CT. Eur J Nucl Med Mol Imaging 2022; 49:3401–3411.
Oriuchi N, Endoh H, Kaira K. Monitoring of current cancer therapy by positron emission tomography and possible role of radiomics assessment. Int J Mol Sci 2022; 23:9394.
Dane B, Grechushkin V, Plank A, Moore W, Bilfinger T. PET/CT vs. non-contrast CT alone for surveillance 1-year post lobectomy for stage I non-small-cell lung cancer. Am J Nucl Med Mol Imaging 2013; 3:408–416.
Kremer R, Peysakhovich Y, Dan LF, Guralnik L, Kagna O, Nir RR, et al. FDG PET/CT for assessing the resectability of NSCLC patients with N2 disease after neoadjuvant therapy. Ann Nucl Med 2016; 30:114–121.
Gamal GH. The usefulness of 18F-FDG PET/CT in follow-up and recurrence detection for patients with lung carcinoma and its impact on the survival outcome. Egypt J Radiol Nucl Med 2021; 52:121.
Moon SH, Cho SH, Park LC, Ji JH, Sun JM, Ahn JS, et al. Metabolic response evaluated by 18F-FDG PET/CT as a potential screening tool in identifying a subgroup of patients with advanced non-small cell lung cancer for immediate maintenance therapy after first-line chemotherapy. Eur J Nucl Med Mol Imaging 2013; 40:1005–1013.
Toba H, Kawakita N, Takashima M, Matsumoto D, Takizawa H, Otsuka H, et al. Diagnosis of recurrence and follow-up using FDG-PET/CT for postoperative non-small-cell lung cancer patients. Gen Thorac Cardiovasc Surg 2021; 69:311–317.
Marcus C, Tajmir SH, Rowe SP, Sheikhbahaei S, Solnes LB. 18F-FDG PET/CT for response assessment in lung cancer. Semin Nucl Med 2022; 52:662–672.
Mac Manus MP, Hicks RJ, Matthews JP, McKenzie A, Rischin D, Salminen EK, et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2003; 21:1285–1292.
Erasmus JJ, Gladish GW, Broemeling L, Sabloff BS, Truong MT, Herbst RS, et al. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: Implications for assessment of tumor response. J Clin Oncol 2003; 21:2574–2582.
William WN, Pataer A, Kalhor N, Correa AM, Rice DC, Wistuba II, et al.; University of Texas M.D. Anderson Lung Cancer Collaborative Research Group. Computed tomography recist assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy. J Thorac Oncol 2013; 8:222–228.
Sheikhbahaei S, Mena E, Marcus C, Wray R, Taghipour M, Subramaniam RM. 18F-FDG PET/CT: Therapy response assessment interpretation (Hopkins criteria) and survival outcomes in lung cancer patients. J Nucl Med 2016; 57:855–860.
Chaft JE, Dunphy M, Naidoo J, Travis WD, Hellmann M, Woo K, et al. Adaptive neoadjuvant chemotherapy guided by 18F-FDG PET in resectable non-small cell lung cancers: The NEOSCAN trial. J Thoraci Oncol 2016; 11:537–544.
van Loon J, Grutters JPC, Wanders R, Boersma L, Dingemans AMC, Bootsma G, et al. 18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: An economic evaluation. Eur J Cancer 2010; 46:110–119.
Van Elmpt W, Ol̈lers M, Dingemans AMC, Lambin P, De Ruysscher D. Response assessment using 18F-FDG PET early in the course of radiotherapy correlates with survival in advanced-stage non-small cell lung cancer. J Nucl Med 2012; 53:1514–1520.
Hicks RJ. The value of the standardized uptake value (SUV) and metabolic tumor volume (MTV) in lung cancer. Semin Nucl Med 2022; 52:734–744.
Boellaard R. Standards for PET image acquisition and quantitative data analysis. . J Nucl Med 2009; 50 (Suppl 1):11S–20S.
Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: Version 1.0. Eur J Nucl Med Mol Imaging 2010; 37:181–200.